Latest Ratios: P/E Ratio -2.1x · EV/EBITDA N/A · ROE -745.2%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $57M | $49M | $44M | $16M | $33M | — | — | — |
| Enterprise Value | $-8601201417 | $-8608895050 | $34M | $8M | $22M | — | — | — |
| P/E Ratio → | -2.10 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 19.87 | 20.68 | 12.09 | 32.49 | 3.83 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -745.2% | -745.2% | -1131.0% | -440.1% | -178.3% | -330.6% | — | -490.1% |
| ROA | -225.5% | -225.5% | -262.4% | -201.9% | -135.1% | -207.1% | -535.0% | -374.3% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -476.2% | -476.2% | -378.7% | -354.6% | -180.4% | -189.1% | -3380.3% | -508.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 0.03 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -3644.16 | -2.64 | -14.97 | -1.29 | -1.15 | — | -1.26 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -407975.42 | — | -2262.42 | -14.20 | -221.12 | — |
Net cash position: cash ($8.7B) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | 1.66 | 2.65 | 1.53 | 3.61 | 4.97 | 0.44 | 4.63 |
| Quick Ratio | 1.66 | 1.66 | 2.65 | 1.53 | 3.61 | 4.97 | 0.44 | 4.63 |
| Cash Ratio | 1483.45 | 1483.45 | 2.51 | 1.45 | 3.35 | 4.93 | 0.39 | 4.56 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $32M | $22M | $13M | $9M | $11M | $11M | $11M |
Binary clinical trial failure
Based on reported figures, MAIA's P/B ratio of 19.06 suggests a significant premium relative to its book value, which appears disconnected from the firm's pre-revenue status and the inherent binary risks associated with its lead oncology asset, THIO, as noted in recent financial disclosures.
The elevated P/B multiple likely reflects market anticipation of clinical trial success rather than tangible asset backing. Investors should monitor whether this valuation premium can be sustained as the company continues to burn cash without a clear path to commercial revenue generation.
As reported in financial statements, MAIA currently exhibits no meaningful profitability metrics, with net margins remaining consistently negative as the firm prioritizes the THIO-101 clinical trial over operational efficiency, a standard but high-risk profile for early-stage biotechnology companies operating without commercialized products.
The absence of gross or operating margins underscores the firm's reliance on external capital to fund its research pipeline. Any interpretation of earning power is premature until the company demonstrates a successful clinical readout that could potentially lead to licensing or milestone-based revenue streams.
According to recent SEC filings, the company's current ratio reached 5.59 in 2026Q1, yet this figure is heavily distorted by an unexplained $8.6 billion cash anomaly in 2025Q4, which warrants extreme caution and immediate verification before assessing the firm's actual operational runway or solvency.
The reported liquidity metrics appear fundamentally inconsistent with the company's micro-cap status and historical cash burn. Analysts should treat these figures as unreliable until management provides a reconciliation that clarifies the firm's true cash position and ability to fund ongoing clinical operations.
Based on reported figures, the current ratio is the most commonly misapplied metric for MAIA, as it obscures the company's actual cash burn rate and reliance on external financing by failing to account for the binary nature of clinical-stage biotechnology development and potential data integrity issues.
Using standard liquidity ratios for a pre-revenue firm ignores the reality that 'current assets' may be tied to restricted clinical trial funding or subject to reporting errors. A more appropriate metric would be 'Net Cash Burn' relative to the remaining clinical trial timeline, which provides a clearer view of the firm's operational survival horizon.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MAIA stock.
MAIA Biotechnology, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
MAIA Biotechnology, Inc.'s return on equity (ROE) is -745.2%. The historical average is -359.8%.
Based on historical data, MAIA Biotechnology, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.